NEW DELHI: The Indian Patent Office has rejected the grant of a patent for dolutegravir , a crucial HIV drug marketed by Viiv Healthcare , facilitating the entry of generics and expanding access to affordable, life-saving treatment. The decision, announced after a contentious nearly decade-long battle, follows the company's patent application for the HIV treatment in 2007.
The company faced multiple pre-grant oppositions from Natco and various advocacy groups between 2013 and 2019, according to the order accessed by TOI. It led to the Patent Office rejecting the grant of a patent recently. Experts believe the ruling could serve as an example against the practice of " evergreening " patents, a practice that extends patent life through patenting of obvious forms and improvements of life-saving medicines. Over the next few years, with more players entering the market, the first-line HIV drug will likely be available at a fraction of the innovator price.
"I am of the opinion that claims are not patentable under Section 3(d) of the Act since no enhanced therapeutic efficacy has been demonstrated in the specification," the order by Deputy Controller D Usha Rao said.
Viiv Healthcare, which is majority owned by GSK and has Pfizer and Shionogi as major shareholders, is focused on HIV therapies. In April 2014, the Medicines Patent Pool and ViiV Healthcare signed licensing agreements to accelerate access to dolutegravir, for adult and paediatric care.
The company faced multiple pre-grant oppositions from Natco and various advocacy groups between 2013 and 2019, according to the order accessed by TOI. It led to the Patent Office rejecting the grant of a patent recently. Experts believe the ruling could serve as an example against the practice of " evergreening " patents, a practice that extends patent life through patenting of obvious forms and improvements of life-saving medicines. Over the next few years, with more players entering the market, the first-line HIV drug will likely be available at a fraction of the innovator price.
"I am of the opinion that claims are not patentable under Section 3(d) of the Act since no enhanced therapeutic efficacy has been demonstrated in the specification," the order by Deputy Controller D Usha Rao said.
Viiv Healthcare, which is majority owned by GSK and has Pfizer and Shionogi as major shareholders, is focused on HIV therapies. In April 2014, the Medicines Patent Pool and ViiV Healthcare signed licensing agreements to accelerate access to dolutegravir, for adult and paediatric care.
You may also like
Starlink Sets Its Sights on India: Musk's Vision for Better Connectivity
'I tried the new McDonald's mini hash browns - I have one major issue with them'
The best value gaming headset is about to get even better
Mappable forms strategic partnerships with Fujairah GIS Center, Emirates Transport and Emarat at GITEX 2024
Amanda Holden sparks BGT outrage as 'fake' announcement heard in background of new video
Kyran Durnin's mum left chilling note behind on table before vanishing with her son, 8
BSF seizes 2.75 kg gold along Indo-B'desh border, 3 farmers held
My 70-year-old dad swears by this M&S thermal top for keeping him warm in winter
Meet the mind guru helping 'goofy and loving' Wigan Warriors boss Matt Peet
'No Stick-Waving Or Aggressive Gestures': Omar Abdullah, In First Move As J&K CM, Sets New VIP Protocol
New Zealand exempts abuse victims from forced 2-year wait before they can seek divorce
Four Bangladeshis arrested along IBB with fake Aadhaar cards
Lionel Scaloni comments after Lionel Messi hat-trick sum it all up as retirement hint dropped
Sensex Slips 319 Points, Nifty Dips Below 25K: Auto & IT Stocks Drag
SCO meeting: Pakistan PM Shehbaz Sharif stays silent on Kashmir
Govt approves Rs 35,000 cr for PM Annadata Aay Sanrakshan Abhiyan
'My son has come back': Murdered fan Renukaswamy's father as grandson born
Alastair Cook, Neetu David And AB De Villiers Inducted Into The ICC Hall Of Fame As Class Of 2024
'Stylish' ankle wellies are 'so comfortable and a godsend in wet weather' - and under £20
Diwali BONANZA! Haryana anganwadi workers salary hike announced ahead of festival